<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996617</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongPH02</org_study_id>
    <nct_id>NCT02996617</nct_id>
  </id_info>
  <brief_title>PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia</brief_title>
  <official_title>PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor
      to limit the dosage and the continuation of chemotherapy. The PEG-rhG-CSF has increased
      plasma half-life, and prolonged efficacy in compare with rhG-CSF. The purpose of this study
      is to determine the safety and effectiveness of PEG-rhG-CSF in preventing neutropenia
      following chemotherapy in patients with non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neutropenia is a common clinical complication of chemotherapy in cancer patients. It is an
      important factor that delays the course of standard treatments in patients. Recombinant human
      granulocyte colony-stimulating factor (rhG-CSF) is an effective drug for the treatment of
      chemotherapy-induced neutropenia. However, for patients with neutropenia, multiple rhG-CSF
      treatments are usually required. This is likely to extend the antitumor treatment period and
      increase physical and mental stress in patients. Pegylated recombinant human granulocyte
      colony-stimulating factor (PEG-rhG-CSF) is rhG-CSF chemically modified by a single methoxy
      polyethylene glycol group; it is able to alleviate neutropenia with a single dose. The aim of
      the present study was to determine the safety and effectiveness of preventive treatment with
      pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) on concurrent
      chemotherapy-induced neutropenia and to provide a rational basis for its clinical
      application. Therefore, the investigators designed the multi-center, open-label,randomized
      controlled clinical study and aimed to compare the efficacy and safety between PEG-rhG-CSF
      and rhG-CSF in non-Hodgkin lymphoma receiving chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade 3/4 neutropenia（neutrophils≤1×10^ 9/L） in every cycle</measure>
    <time_frame>through the study completion,an average of 4 months</time_frame>
    <description>Proportion of patients grade 3/4 neutropenia（neutrophils≤1×10^ 9/L）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of the chemotherapy delay</measure>
    <time_frame>through the study completion,an average of 4 months</time_frame>
    <description>Proportion of chemotherapy delay(&gt;7 days) caused by neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the febrile neutropenia in every cycle</measure>
    <time_frame>through the study completion,an average of 4 months</time_frame>
    <description>Proportion of febrile caused by neutropenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Lymphoma,Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>rhG-CSF regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L for total 4 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated rhG-CSF regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF regimen</intervention_name>
    <description>Patients weren't preventive use of rhG-CSF.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin</description>
    <arm_group_label>rhG-CSF regimen</arm_group_label>
    <other_name>Pegylated rhG-CSF regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated rhG-CSF regimen</intervention_name>
    <description>Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin</description>
    <arm_group_label>Pegylated rhG-CSF regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Investigator diagnosis of non-Hodgkin lymphoma(Highly invasive lymphoma/Burkitt
             lymphoma were excluded)

          -  Age 18 to 80 years

          -  ECOG performance status ≤ 2

          -  receive multi-cycle Chemotherapy naive

          -  grade 3/4 neutropenia occurred in the patient's first cycle chemotherapy or the risk
             of neutropenia ＞20% without rhG-CSF support

          -  Expected survival time≥3 months; cNormal bone marrow function(absolute neutrophil
             count ≥1.5 × 109/L; platelet count ≥ 80 × 109/L)

          -  Liver function: transaminase≤2.5× upper limit of normal value，bilirubin≤2.5×upper
             limit of normal value; serum creatinine≤2×upper limit of normal value;

        Exclusion Criteria:

          -  Patients with severe complications or severe infection;

          -  Invasion of central nervous system;

          -  Patients with severe visceral organ dysfunction, heart block, myocardial infarction
             within 6 months;

          -  Prior bone marrow stem cell or organ transplantation

          -  patients with severe allergic constitution, or those who are allergic to Escherichia
             coli products; 5. Patients participate in other clinical studies within 4 weeks;

          -  Pregnancy, lactation

          -  Other patients who are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xin wang, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xin wang, MD, PHD</last_name>
    <phone>86-531-68778331</phone>
    <email>xinw007@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>changqing zhen, MD</last_name>
    <phone>86-531-68778331</phone>
    <email>zcq1521@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jin'an</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD, PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>xinw007@126.com</email>
    </contact>
    <contact_backup>
      <last_name>changqing zhen, MD</last_name>
      <phone>86-531-68778331</phone>
      <email>zcq1521@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003 Jan;14(1):29-35.</citation>
    <PMID>12488289</PMID>
  </reference>
  <reference>
    <citation>Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002 Jun;13(6):903-9.</citation>
    <PMID>12123336</PMID>
  </reference>
  <reference>
    <citation>Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000 Jul;18(13):2522-8.</citation>
    <PMID>10893282</PMID>
  </reference>
  <reference>
    <citation>Hadji P, Kostev K, Schröder-Bernhardi D, Ziller V. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012 Apr;50(4):281-9. Erratum in: Int J Clin Pharmacol Ther. 2012 Jul;50(7):532.</citation>
    <PMID>22456299</PMID>
  </reference>
  <reference>
    <citation>Wen TJ, Wen YW, Chien CR, Chiang SC, Hsu WW, Shen LJ, Hsiao FY. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system. J Eval Clin Pract. 2017 Apr;23(2):288-293. doi: 10.1111/jep.12597. Epub 2016 Aug 4.</citation>
    <PMID>27491287</PMID>
  </reference>
  <reference>
    <citation>Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anticancer Drugs. 2013 Jul;24(6):641-7. doi: 10.1097/CAD.0b013e3283610b5d.</citation>
    <PMID>23571496</PMID>
  </reference>
  <reference>
    <citation>Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev. 2002 Apr;28 Suppl A:13-6. Review.</citation>
    <PMID>12173407</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Director of Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>Lymphomas Non-Hodgkin's B-Cell</keyword>
  <keyword>Lymphomas Non-Hodgkin's T-Cell</keyword>
  <keyword>PEG-rhG-CSF</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

